BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hou J, Zhang H, Sun B, Karin M. The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications. J Hepatol 2020;72:167-82. [PMID: 31449859 DOI: 10.1016/j.jhep.2019.08.014] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 15.7] [Reference Citation Analysis]
Number Citing Articles
1 Vacani-Martins N, Meuser-Batista M, Dos Santos CLP, Hasslocher-Moreno AM, Henriques-Pons A. The Liver and the Hepatic Immune Response in Trypanosoma cruzi Infection, a Historical and Updated View. Pathogens 2021;10:1074. [PMID: 34578107 DOI: 10.3390/pathogens10091074] [Reference Citation Analysis]
2 Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52:1898-1907. [PMID: 33268834 DOI: 10.1038/s12276-020-00527-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
3 Gao X, Huang H, Wang Y, Pan C, Yin S, Zhou L, Zheng S. Tumor Immune Microenvironment Characterization in Hepatocellular Carcinoma Identifies Four Prognostic and Immunotherapeutically Relevant Subclasses. Front Oncol 2020;10:610513. [PMID: 33680932 DOI: 10.3389/fonc.2020.610513] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Xu Y, Zhang Z, Xu D, Yang X, Zhou L, Zhu Y. Identification and integrative analysis of ACLY and related gene panels associated with immune microenvironment reveal prognostic significance in hepatocellular carcinoma. Cancer Cell Int 2021;21:409. [PMID: 34344378 DOI: 10.1186/s12935-021-02108-2] [Reference Citation Analysis]
5 Xia X, Tang P, Liu H, Li Y. Identification and Validation of an Immune-related Prognostic Signature for Hepatocellular Carcinoma. J Clin Transl Hepatol 2021;9:798-808. [PMID: 34966643 DOI: 10.14218/JCTH.2021.00017] [Reference Citation Analysis]
6 Kamimura K, Yokoo T, Abe H, Terai S. Gene Therapy for Liver Cancers: Current Status from Basic to Clinics. Cancers (Basel) 2019;11:E1865. [PMID: 31769427 DOI: 10.3390/cancers11121865] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
7 Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX, Finn RS. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 2021. [PMID: 34764464 DOI: 10.1038/s41571-021-00573-2] [Reference Citation Analysis]
8 He Q, Liu M, Huang W, Chen X, Zhang B, Zhang T, Wang Y, Liu D, Xie M, Ji X, Sun M, Tian D, Xia L. IL-1β-Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1. Hepatology 2021. [PMID: 34288020 DOI: 10.1002/hep.32062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Wu Y, Zhang J, Li Q. Autophagy, an accomplice or antagonist of drug resistance in HCC? Cell Death Dis 2021;12:266. [PMID: 33712559 DOI: 10.1038/s41419-021-03553-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Cao S, Liu M, Sehrawat TS, Shah VH. Regulation and functional roles of chemokines in liver diseases. Nat Rev Gastroenterol Hepatol 2021;18:630-47. [PMID: 33976393 DOI: 10.1038/s41575-021-00444-2] [Reference Citation Analysis]
11 Weng J, Zhou C, Zhou Q, Chen W, Yin Y, Atyah M, Dong Q, Shi Y, Ren N. Development and Validation of a Metabolic Gene-Based Prognostic Signature for Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:193-209. [PMID: 33824863 DOI: 10.2147/JHC.S300633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Gupta R, Kleinjans J, Caiment F. Identifying novel transcript biomarkers for hepatocellular carcinoma (HCC) using RNA-Seq datasets and machine learning. BMC Cancer 2021;21:962. [PMID: 34445986 DOI: 10.1186/s12885-021-08704-9] [Reference Citation Analysis]
13 Desjonqueres E, Campani C, Marra F, Zucman-Rossi J, Nault JC. Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice. Liver Int 2022. [PMID: 34982503 DOI: 10.1111/liv.15152] [Reference Citation Analysis]
14 Khatun M, Ray R, Ray RB. Hepatitis C virus associated hepatocellular carcinoma. Adv Cancer Res 2021;149:103-42. [PMID: 33579422 DOI: 10.1016/bs.acr.2020.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Liu Z, Liu L, Lu T, Wang L, Li Z, Jiao D, Han X. Hypoxia Molecular Characterization in Hepatocellular Carcinoma Identifies One Risk Signature and Two Nomograms for Clinical Management.J Oncol. 2021;2021:6664386. [PMID: 33552157 DOI: 10.1155/2021/6664386] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Lyu N, Zeng Y, Kong Y, Chen Q, Deng H, Ou S, Bai Y, Tang H, Wang X, Zhao M. Ferroptosis is involved in the progression of hepatocellular carcinoma through the circ0097009/miR-1261/SLC7A11 axis. Ann Transl Med 2021;9:675. [PMID: 33987373 DOI: 10.21037/atm-21-997] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
17 Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2022;23:77-90. [PMID: 34914889 DOI: 10.1016/S1470-2045(21)00604-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Lei Y, Wang S, Liu J, Yan W, Han P, Tian D. Identification of MCM family as potential therapeutic and prognostic targets for hepatocellular carcinoma based on bioinformatics and experiments. Life Sci 2021;272:119227. [PMID: 33607151 DOI: 10.1016/j.lfs.2021.119227] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Wang H, Calvisi DF, Chen X. Organoids for the Study of Liver Cancer. Semin Liver Dis 2021;41:19-27. [PMID: 33764482 DOI: 10.1055/s-0040-1719176] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Bresnahan E, Lindblad KE, Ruiz de Galarreta M, Lujambio A. Mouse Models of Oncoimmunology in Hepatocellular Carcinoma. Clin Cancer Res 2020;26:5276-86. [PMID: 32327473 DOI: 10.1158/1078-0432.CCR-19-2923] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Ko BS, Liang SM, Chang TC, Wu JY, Lee PH, Hsu YJ, Kuo CC, Liou JY, Wu KK. Association of Tumor Hydroxyindole O-Methyltransferase and Serum 5-Methoxytryptophan with Long-Term Survival of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5311. [PMID: 34771474 DOI: 10.3390/cancers13215311] [Reference Citation Analysis]
22 Sun L, Gao F, Gao Z, Ao L, Li N, Ma S, Jia M, Li N, Lu P, Sun B, Ho M, Jia S, Ding T, Gao W. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma. J Immunother Cancer 2021;9:e001875. [PMID: 33833049 DOI: 10.1136/jitc-2020-001875] [Reference Citation Analysis]
23 Xin F, Wu M, Cai Z, Zhang X, Wei Z, Liu X, Liu J. Tumor Microenvironment Triggered Cascade-Activation Nanoplatform for Synergistic and Precise Treatment of Hepatocellular Carcinoma. Adv Healthc Mater 2021;10:e2002036. [PMID: 33644987 DOI: 10.1002/adhm.202002036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Ding LH, Yu Y, Edmondson EF, Weil MM, Pop LM, McCarthy M, Ullrich RL, Story MD. Transcriptomic analysis links hepatocellular carcinoma (HCC) in HZE ion irradiated mice to a human HCC subtype with favorable outcomes. Sci Rep 2021;11:14052. [PMID: 34234215 DOI: 10.1038/s41598-021-93467-3] [Reference Citation Analysis]
25 Heinrich B, Gertz EM, Schäffer AA, Craig A, Ruf B, Subramanyam V, McVey JC, Diggs LP, Heinrich S, Rosato U, Ma C, Yan C, Hu Y, Zhao Y, Shen TW, Kapoor V, Telford W, Kleiner DE, Stovroff MK, Dhani HS, Kang J, Fishbein T, Wang XW, Ruppin E, Kroemer A, Greten TF, Korangy F. The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma. Gut 2021:gutjnl-2021-325288. [PMID: 34340996 DOI: 10.1136/gutjnl-2021-325288] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Weinmann A, Galle PR. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions. Curr Oncol 2020;27:S152-64. [PMID: 33343209 DOI: 10.3747/co.27.7315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Schmidt-Arras D, Galun E, Rose-John S. The two facets of gp130 signalling in liver tumorigenesis. Semin Immunopathol 2021. [PMID: 34047814 DOI: 10.1007/s00281-021-00861-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Arjunan V, Hansen A, Deutzmann A, Sze DY, Dhanasekaran R. Spontaneous Regression of Hepatocellular Carcinoma: When the Immune System Stands Up to Cancer. Hepatology 2021;73:1611-4. [PMID: 32740961 DOI: 10.1002/hep.31489] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Ma XL, Tang WG, Yang MJ, Xie SH, Wu ML, Lin G, Lu RQ. Serum STIP1, a Novel Indicator for Microvascular Invasion, Predicts Outcomes and Treatment Response in Hepatocellular Carcinoma. Front Oncol 2020;10:511. [PMID: 32426271 DOI: 10.3389/fonc.2020.00511] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
30 Huang H, Tan M, Zheng L, Yan G, Li K, Lu D, Cui X, He S, Lei D, Zhu B, Zhao J. Prognostic Implications of the Complement Protein C1Q and Its Correlation with Immune Infiltrates in Osteosarcoma. Onco Targets Ther 2021;14:1737-51. [PMID: 33707956 DOI: 10.2147/OTT.S295063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
31 Liu X, Ren H, Guo H, Wang W, Zhao N. Interleukin-35 has a tumor-promoting role in hepatocellular carcinoma. Clin Exp Immunol 2021;203:219-29. [PMID: 33030251 DOI: 10.1111/cei.13535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 He F, Antonucci L, Karin M. NRF2 as a regulator of cell metabolism and inflammation in cancer. Carcinogenesis 2020;41:405-16. [PMID: 32347301 DOI: 10.1093/carcin/bgaa039] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
33 Li Y, Zou L, Liu X, Luo J, Liu H. Identification of Immune-Related Genes for Establishment of Prognostic Index in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:760079. [PMID: 34796177 DOI: 10.3389/fcell.2021.760079] [Reference Citation Analysis]
34 Dolicka D, Sobolewski C, Correia de Sousa M, Gjorgjieva M, Foti M. mRNA Post-Transcriptional Regulation by AU-Rich Element-Binding Proteins in Liver Inflammation and Cancer. Int J Mol Sci 2020;21:E6648. [PMID: 32932781 DOI: 10.3390/ijms21186648] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
35 He F, Ru X, Wen T. NRF2, a Transcription Factor for Stress Response and Beyond. Int J Mol Sci 2020;21:E4777. [PMID: 32640524 DOI: 10.3390/ijms21134777] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 32.0] [Reference Citation Analysis]
36 Myojin Y, Hikita H, Sugiyama M, Sasaki Y, Fukumoto K, Sakane S, Makino Y, Takemura N, Yamada R, Shigekawa M, Kodama T, Sakamori R, Kobayashi S, Tatsumi T, Suemizu H, Eguchi H, Kokudo N, Mizokami M, Takehara T. Hepatic Stellate Cells in Hepatocellular Carcinoma Promote Tumor Growth Via Growth Differentiation Factor 15 Production. Gastroenterology 2021;160:1741-1754.e16. [PMID: 33346004 DOI: 10.1053/j.gastro.2020.12.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
37 Nishida N, Kudo M. Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1274. [PMID: 32443599 DOI: 10.3390/cancers12051274] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
38 Liu H, Li D, Zhou L, Kan S, He G, Zhou K, Wang L, Chen M, Shu W. LMNA functions as an oncogene in hepatocellular carcinoma by regulating the proliferation and migration ability. J Cell Mol Med 2020;24:12008-19. [PMID: 32896989 DOI: 10.1111/jcmm.15829] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
39 Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 96] [Cited by in F6Publishing: 108] [Article Influence: 96.0] [Reference Citation Analysis]
40 Lee AQ, Li Y, Gong Z. Inducible Liver Cancer Models in Transgenic Zebrafish to Investigate Cancer Biology. Cancers (Basel) 2021;13:5148. [PMID: 34680297 DOI: 10.3390/cancers13205148] [Reference Citation Analysis]
41 Liu Z, Zhang Y, Shi C, Zhou X, Xu K, Jiao D, Sun Z, Han X. A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma. J Transl Med 2021;19:5. [PMID: 33407585 DOI: 10.1186/s12967-020-02697-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
42 He Y, Dang Q, Li J, Zhang Q, Yu X, Xue M, Guo W. Prediction of hepatocellular carcinoma prognosis based on expression of an immune-related gene set. Aging (Albany NY) 2020;12:965-77. [PMID: 31929113 DOI: 10.18632/aging.102669] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
43 Ribas V, de la Rosa LC, Robles D, Núñez S, Segalés P, Insausti-Urkia N, Solsona-Vilarrasa E, Fernández-Checa JC, García-Ruiz C. Dietary and Genetic Cholesterol Loading Rather Than Steatosis Promotes Liver Tumorigenesis and NASH-Driven HCC. Cancers (Basel) 2021;13:4091. [PMID: 34439245 DOI: 10.3390/cancers13164091] [Reference Citation Analysis]
44 Cadoux M, Caruso S, Pham S, Gougelet A, Pophillat C, Riou R, Loesch R, Colnot S, Nguyen CT, Calderaro J, Celton-morizur S, Guerra N, Zucman-rossi J, Desdouets C, Couty J. Expression of NKG2D ligands is downregulated by β-catenin signalling and associates with HCC aggressiveness. Journal of Hepatology 2021;74:1386-97. [DOI: 10.1016/j.jhep.2021.01.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
45 Refolo MG, Messa C, Guerra V, Carr BI, D'Alessandro R. Inflammatory Mechanisms of HCC Development. Cancers (Basel) 2020;12:E641. [PMID: 32164265 DOI: 10.3390/cancers12030641] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
46 Kamimura K, Yokoo T, Abe H, Sakai N, Nagoya T, Kobayashi Y, Ohtsuka M, Miura H, Sakamaki A, Kamimura H, Miyamura N, Nishina H, Terai S. Effect of Diphtheria Toxin-Based Gene Therapy for Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E472. [PMID: 32085552 DOI: 10.3390/cancers12020472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
47 Tan S, Zhao J, Sun Z, Cao S, Niu K, Zhong Y, Wang H, Shi L, Pan H, Hu J, Qian L, Liu N, Yuan J. Hepatocyte-specific TAK1 deficiency drives RIPK1 kinase-dependent inflammation to promote liver fibrosis and hepatocellular carcinoma. Proc Natl Acad Sci U S A 2020;117:14231-42. [PMID: 32513687 DOI: 10.1073/pnas.2005353117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
48 Lin Z, Xie YZ, Zhao MC, Hou PP, Tang J, Chen GL. Xanthine dehydrogenase as a prognostic biomarker related to tumor immunology in hepatocellular carcinoma. Cancer Cell Int 2021;21:475. [PMID: 34496841 DOI: 10.1186/s12935-021-02173-7] [Reference Citation Analysis]
49 Hung HC, Lee JC, Wang YC, Cheng CH, Wu TH, Lee CF, Wu TJ, Chou HS, Chan KM, Lee WC. Response Prediction in Immune Checkpoint Inhibitor Immunotherapy for Advanced Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1607. [PMID: 33807219 DOI: 10.3390/cancers13071607] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Wu KK. Cytoguardin: A Tryptophan Metabolite against Cancer Growth and Metastasis. Int J Mol Sci 2021;22:4490. [PMID: 33925793 DOI: 10.3390/ijms22094490] [Reference Citation Analysis]
51 Cheu JW, Wong CC. Mechanistic Rationales Guiding Combination Hepatocellular Carcinoma Therapies Involving Immune Checkpoint Inhibitors. Hepatology 2021. [PMID: 33811765 DOI: 10.1002/hep.31840] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Lyu N, Yi JZ, Zhao M. Immunotherapy in older patients with hepatocellular carcinoma. Eur J Cancer 2021;162:76-98. [PMID: 34954439 DOI: 10.1016/j.ejca.2021.11.024] [Reference Citation Analysis]
53 Seckler F, Doussot A, Colpart P, Turco C, Calame P, Aubin F, Algros MP, Borg C, Nardin C, Heyd B. Preoperative immunotherapy for resectable hepatocellular carcinoma: Toward a paradigm shift? J Hepatol 2020;73:1588-90. [PMID: 32951909 DOI: 10.1016/j.jhep.2020.05.048] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Chambers A, Kundranda M, Rao S, Mahmoud F, Niu J. Anti-angiogenesis Revisited: Combination with Immunotherapy in Solid Tumors. Curr Oncol Rep 2021;23:100. [PMID: 34269922 DOI: 10.1007/s11912-021-01099-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]